Lymphoma

PFS, OS Improved With Sequential Rituximab/Bendamustine, Rituximab/Cytarabine in Untreated Mantle Cell Lymphoma

PFS, OS Improved With Sequential Rituximab/Bendamustine, Rituximab/Cytarabine in Untreated Mantle Cell Lymphoma

By

Two simultaneous studies demonstrate improved progression-free survival and overall survival in patients with uMCL who receive induction therapy with RB/RC followed by ASCT.

A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL

A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL

By

Checkpoint-based therapies may sensitize patients to subsequent therapies.

The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients

The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients

[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.

Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma

Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma

By

A review of therapy options for relapsed/refractory DLBCL and FL compared SCT with chemotherapy/immunotherapy and experimental regimes. Patients fared better with SCT than other treatment modalities.

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress

By

A retrospective evaluation of patients treated at a tertiary cancer center demonstrated that patients with Hodgkin lymphoma experienced periods of actionable distress in survivorship, despite a low overall distress burden.

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

Commission Seeks Standardized Adverse Event Assessments in Hematologic Malignancies

By

A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.

Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphomas Identified

Risk Factors for Higher-Grade Transformation in Marginal Zone Lymphomas Identified

By

In a retrospective evaluation, investigators sought to identify risk factors for higher-grade transformation in patients with marginal zone lymphomas.

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

Cost of Brentuximab Vedotin as First-Line Therapy for Advanced Hodgkin Lymphoma Prohibitive

By

Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.

Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment

Navigation at the End of Therapy: A Crucial Transition in Lymphoma Treatment

By

A nurse-led study explored the significance of nurse navigators for patients with lymphoma approaching their transition from acute care to survivorship care.

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

Newer Hodgkin Lymphoma Regimens Are Less Toxic, But Still Impose Reproductive Risks

By

A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin

By

A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

Rituximab Maintenance Improved Long-Term Survival in Elderly With Follicular Lymphoma

By

A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.

Insurance Status Influences Overall Survival in Follicular Lymphoma

Insurance Status Influences Overall Survival in Follicular Lymphoma

By

Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

RiBVD Effective in the First-Line Setting for Mantle Cell Lymphoma

By

Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

Lenalidomide Plus R-CHOP Effective in High-Burden Follicular Lymphoma

By

A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

By

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era

[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL

By

A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma

By

Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

By

Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

Radiation-Induced Esophagitis: A Common, Debilitating Clinical Challenge in Thoracic Radiotherapy

By

A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

Dual Inhibitor for Treating CLL/SLL, Follicular Lymphoma Granted Priority Review

By

Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

PET Use May Allow Early Treatment Adjustment in Non-Hodgkin Lymphoma

By

The ability to make early adjustments to treatment has the potential to improve survival.

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Nurse-led Interventions Improve Quality of Life for Lymphoma Survivors

Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

Management of Relapsed/Refractory Marginal Zone Lymphoma: Focus on Ibrutinib

[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

By

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

Fifth Indication for Brentuximab Vedotin Is a First for cHL Therapy in 40+ Years

By

FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

18F-FDG PET/CT Accurately Identifies Bone Marrow Involvement in Pediatric Hodgkin's Lymphoma

By

Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma

By

In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

Complementary and Alternative Medicine Practices of Lymphoma Survivors in South Korea

By

A study from South Korea determined the prevalence and type of CAM practices lymphoma survivors used for various purposes including ease symptoms, augment treatment, boost immunity, and gain a sense of control.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs